HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
Sep, 2024
HANGZHOU, China, September 12, 2024 – The recombinant humanized anti-EGFR-CD3 enzyme-controlled bispecific antibody (hereinafter referred to as CMDE005), developed by Centrymed based on its proprietary dual-antibody platform, proBiTE, has been approved for clinical trials by the NMPA for the treatment of various EGFR-positive advanced solid tumors.
As the pharmaceutical research collaborator for the IND application of the CMDE005 project, HJB extends warm congratulations on the approval of this project for clinical trials.
CDMO@hjbbio.com
